Figure 29 depicts a chart of Odds ratio of myleotoxicity during thiopurine treatment of chronic autoimmune disease, homozygotes versus noncarriers. The results are odds ratio of 2.20 with a confidence interval of 95 percent (0.15, 32.8) favoring noncarriers.

Figure 29Odds ratio of myelotoxicity during thiopurine treatment of chronic autoimmune disease, homozygotes versus noncarriers

From: 3, Results

Cover of Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs
Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs.
Evidence Reports/Technology Assessments, No. 196.
Booth RA, Ansari MT, Tricco AC, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.